PC
ACHN

Palo Capital’s Achillion Pharmaceuticals ACHN Stock Holding History

Palo Capital’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-14,400
Closed -$100K – 154
2015
Q3 		$100K Buy
+14,400
New +$117K 0.09% 120

Other funds holding ACHN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Palo Capital's ACHN Position: Q4 2015 in Review

Palo Capital sold out of Achillion Pharmaceuticals (ACHN) in Q4 2015, closing a stake of 14,400 shares — an estimated $100K sold.

Palo Capital first reported a position in ACHN in Q3 2015 and held it in 1 quarter. The position peaked at $100K in Q3 2015. 152 funds tracked by Wall St. Rank hold ACHN as of Q4 2015.

  • Palo Capital reported no remaining Achillion Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • Palo Capital sold 14,400 Achillion Pharmaceuticals shares in Q4 2015, an estimated $100K.
  • Palo Capital first reported a position in Achillion Pharmaceuticals in Q3 2015 and held it in 1 quarter.
  • Palo Capital's Achillion Pharmaceuticals position peaked at $100K in Q3 2015.
  • 152 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q4 2015.

Based on Palo Capital's 13F filing for Q4 2015, filed 25 Jan 2016.